Triclosan
(TCS) and triclocarban (TCC) are antimicrobial agents
formulated in a wide variety of consumer products (including soaps,
toothpaste, medical devices, plastics, and fabrics) that are regulated
by the U.S. Food and Drug Administration (FDA) and U.S. Environmental
Protection Agency. In late 2014, the FDA will consider regulating
the use of both chemicals, which are under scrutiny regarding lack
of effectiveness, potential for endocrine disruption, and potential
contribution to bacterial resistance to antibiotics. Here, we report
on body burdens of TCS and TCC resulting from real-world exposures
during pregnancy. Using liquid chromatography tandem mass spectrometry,
we determined the concentrations of TCS, TCC, and its human metabolites
(2′-hydroxy-TCC and 3′-hydroxy-TCC) as well as the manufacturing
byproduct (3′-chloro-TCC) as total concentrations (Σ−)
after conjugate hydrolysis in maternal urine and cord blood plasma
from a cohort of 181 expecting mother/infant pairs in an urban multiethnic
population from Brooklyn, NY recruited in 2007–09. TCS was
detected in 100% of urine and 51% of cord blood samples after conjugate
hydrolysis. The interquartile range (IQR) of detected TCS concentrations
in urine was highly similar to the IQR reported previously for the
age-matched population of the National Health and Nutrition Examination
Survey (NHANES) from 2003 to 2004, but typically higher than the IQR
reported previously for the general population (detection frequency
= 74.6%). Urinary levels of TCC are reported here for the first time
from real-world exposures during pregnancy, showing a median concentration
of 0.21 μg/L. Urinary concentrations of TCC correlated well
with its phase-I metabolite ∑-2′-hydroxy-TCC (r = 0.49) and the manufacturing byproduct ∑-3′-chloro-TCC
C (r = 0.79), and ∑-2′-hydroxy-TCC
correlated strongly with ∑-3′-hydroxy-TCC (r = 0.99). This human biomonitoring study presents the first body
burden data for TCC from exposures occurring during pregnancy and
provides additional data on composite exposure to TCS (i.e., from
both consumer-product use and environmental sources) in the maternal–fetal
unit for an urban population in the United States.